- Home
- ADVM vs MAIA Comparison
ADVM vs MAIA Comparison
Compare ADVM & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADVM
- MAIA
- Stock Information
- Founded
- ADVM 2006
- MAIA 2018
- Country
- ADVM United States
- MAIA United States
- Employees
- ADVM N/A
- MAIA N/A
- Industry
- ADVM Biotechnology: Biological Products (No Diagnostic Substances)
- MAIA Biotechnology: Pharmaceutical Preparations
- Sector
- ADVM Health Care
- MAIA Health Care
- Exchange
- ADVM Nasdaq
- MAIA Nasdaq
- Market Cap
- ADVM 66.3M
- MAIA 56.3M
- IPO Year
- ADVM 2014
- MAIA 2022
- Fundamental
- Price
- ADVM $3.54
- MAIA $1.59
- Analyst Decision
- ADVM Strong Buy
- MAIA
- Analyst Count
- ADVM 4
- MAIA 0
- Target Price
- ADVM $19.75
- MAIA N/A
- AVG Volume (30 Days)
- ADVM 84.4K
- MAIA 370.9K
- Earning Date
- ADVM 11-03-2025
- MAIA 08-11-2025
- Dividend Yield
- ADVM N/A
- MAIA N/A
- EPS Growth
- ADVM N/A
- MAIA N/A
- EPS
- ADVM N/A
- MAIA N/A
- Revenue
- ADVM $1,000,000.00
- MAIA N/A
- Revenue This Year
- ADVM $1,836.70
- MAIA N/A
- Revenue Next Year
- ADVM N/A
- MAIA N/A
- P/E Ratio
- ADVM N/A
- MAIA N/A
- Revenue Growth
- ADVM N/A
- MAIA N/A
- 52 Week Low
- ADVM $1.78
- MAIA $1.40
- 52 Week High
- ADVM $8.56
- MAIA $3.74
- Technical
- Relative Strength Index (RSI)
- ADVM 71.73
- MAIA 50.99
- Support Level
- ADVM $2.93
- MAIA $1.46
- Resistance Level
- ADVM $3.25
- MAIA $1.65
- Average True Range (ATR)
- ADVM 0.22
- MAIA 0.09
- MACD
- ADVM 0.05
- MAIA 0.01
- Stochastic Oscillator
- ADVM 95.40
- MAIA 43.10
About ADVM Adverum Biotechnologies Inc.
Adverum Biotechnologies Inc is a clinical-stage company that aims to establish gene therapy as a new standard of care for prevalent ocular diseases. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.